Search Result

Results for "

ABR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) HDAC (3) Isotope-Labeled Compounds (4) NF-κB (4) Reference Standards (3) SARS-CoV (4) Small Interfering RNA (siRNA) (3) TNF Receptor (1) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Inflammation/Immunology (10) Metabolic Disease (4) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141537

ABR-238901 5 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .

HY-100442

Paquinimod Maximum Cited Publications 25 Publications Verification ABR-215757; ABR 25757	SARS-CoV	Metabolic Disease Inflammation/Immunology
Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-13010

Laquinimod 2 Publications Verification ABR-215062	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-13010S

Laquinimod-d5 ABR-215062-d₅	Isotope-Labeled Compounds Apoptosis NF-κB	Inflammation/Immunology
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-RS00110

ABR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABR Human Pre-designed siRNA Set A contains three designed siRNAs for ABR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABR Human Pre-designed siRNA Set A ABR Human Pre-designed siRNA Set A

HY-RS24032

Abr Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abr Rat Pre-designed siRNA Set A contains three designed siRNAs for Abr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abr Rat Pre-designed siRNA Set A Abr Rat Pre-designed siRNA Set A

HY-RS17572

Abr Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abr Mouse Pre-designed siRNA Set A Abr Mouse Pre-designed siRNA Set A

HY-P99436

Anatumomab mafenatox ABR-214936	Transmembrane Glycoprotein	Cardiovascular Disease Inflammation/Immunology Cancer
Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness .

HY-W062904

Laquinimod sodium ABR-215062 sodium	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-100442R

Paquinimod (Standard) ABR-215757 (Standard); ABR 25757 (Standard)	Reference Standards SARS-CoV	Metabolic Disease Inflammation/Immunology
Paquinimod (Standard) is the analytical standard of Paquinimod. This product is intended for research and analytical applications. Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-13010R

Laquinimod (Standard) ABR-215062 (Standard)	Reference Standards NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-13743

Roquinimex Linomide; FCF89; ABR212616	TNF Receptor	Inflammation/Immunology
Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.

HY-10528S

Tasquinimod-d3 ABR-215050-d₃	HDAC Isotope-Labeled Compounds	Cancer
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-100442S

Paquinimod-d5 ABR-215757-d₅; ABR 25757-d₅	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S1

Paquinimod-d5-1 ABR-215757-d₅-1; ABR 25757-d₅-1	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-10528

Tasquinimod 10+ Cited Publications ABR-215050	HDAC	Cancer
Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-10528R

Tasquinimod (Standard) ABR-215050 (Standard)	Reference Standards HDAC	Cancer
Tasquinimod (Standard) is the analytical standard of Tasquinimod. This product is intended for research and analytical applications. Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P99436

Anatumomab mafenatox ABR-214936	Transmembrane Glycoprotein	Cardiovascular Disease Inflammation/Immunology Cancer
Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness .

Species:	Virus (4)
Tag:	His (4)
Source:	HEK293 (3) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73794

	*NA/Neuraminidase Protein, H1N1 (ABR28848, HEK293, His)* NA; Neuraminidase; NA/Neuraminidase Protein, H1N1 (A/Auckland/606/2001, HEK293, His)	Virus	HEK293
	NA/Neuraminidase Protein is a receptor-destroying enzyme that cleaves terminal sialic acids from cellular receptors, potentially facilitating viral invasion of the upper airways by targeting sialic acid moieties on airway epithelial cell mucin. NA plays a pivotal role in viral propagation by catalyzing the removal of terminal sialic acid residues from both viral and cellular glycoconjugates. Moreover, the sialidase activity in late endosome/lysosome traffic appears to enhance virus replication. NA/Neuraminidase Protein, H1N1 (ABR28848, HEK293, His) is the recombinant Virus-derived NA/Neuraminidase protein, expressed by HEK293 , with N-His labeled tag.

HY-P75054

	*HA/Hemagglutinin Protein, H5N1 (ABR10842, HEK293, His)* Influenza A H5N1 (A/China/2006) Hemagglutinin / HA Protein (HEK293, His)	Virus	HEK293
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis.HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions.HA/Hemagglutinin Protein, H5N1 (ABR10842, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P75024

	*HA/Hemagglutinin Protein, H5N9 (ABR37720, sf9, His)* Influenza A H5N9 (A/chicken/Italy/22A/1998) Hemagglutinin / HA Protein (His)	Virus	Sf9 insect cells
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA/Hemagglutinin Protein, H5N9 (ABR37720, sf9, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P74931

	*HA1/Hemagglutinin Protein, H5N9 (ABR37720, HEK293, His)* Influenza A H5N9 (A/chicken/Italy/22A/1998) Hemagglutinin Protein (HA1 Subunit) (His)	Virus	HEK293
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA1/Hemagglutinin Protein, H5N9 (ABR37720, HEK293, His) is the recombinant Virus-derived HA1/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13010S

Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-10528S

Tasquinimod-d3
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

ABR Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ABR Human Pre-designed siRNA Set A contains three designed siRNAs for ABR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abr Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Abr Rat Pre-designed siRNA Set A contains three designed siRNAs for Abr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abr Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Abr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: